Knop, Filip K.

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 142

Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis

Winther-Sørensen, M., Galsgaard, K. D., Santos, A., Trammell, S. A. J., Sulek, K., Kuhre, R. E., Pedersen, J., Andersen, D. B., Hassing, A. S., Dall, M., et al. (2020) · Molecular Metabolism

Liver Disease Diagnosis and TreatmentPancreatic function and diabetes

Cited by 135

Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial

Gudbergsen, H., Overgaard, A., Henriksen, M., Wæhrens, E. E., Bliddal, H., Christensen, R., Nielsen, S. M., Boesen, M., Knop, F. K., Astrup, A., et al. (2021) · The American Journal of Clinical Nutrition

Osteoarthritis Treatment and MechanismsPharmacology and Obesity Treatment

Cited by 131

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial

Aroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 126

Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists

Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 121

Evidence of a liver–alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids

Wewer Albrechtsen, N. J., Færch, K., Jensen, T. M., Witte, D. R., Pedersen, J., Mahendran, Y., Jonsson, A. E., Galsgaard, K. D., Winther-Sørensen, M., Torekov, S. S., et al. (2018) · Diabetologia

Pancreatic function and diabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 119

100 years of glucagon and 100 more

Wewer Albrechtsen, N. J., Holst, J. J., Cherrington, A. D., Finan, B., Gluud, L. L., Dean, E. D., Campbell, J. E., Bloom, S. R., Tan, T. M.-M., Knop, F. K., et al. (2023) · Diabetologia

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 117

Effect of GLP ‐1 receptor agonist treatment on body weight in obese antipsychotic‐treated patients with schizophrenia: a randomized, placebo‐controlled trial

Ishøy, P. L., Knop, F. K., Broberg, B. V., Bak, N., Andersen, U. B., Jørgensen, N. R., Holst, J. J., Glenthøj, B. Y., & Ebdrup, B. H. (2017) · Diabetes, Obesity and Metabolism

Schizophrenia research and treatmentPharmacology and Obesity Treatment

Cited by 102

FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest

Søberg, S., Andersen, E. S., Dalsgaard, N. B., Jarlhelt, I., Hansen, N. L., Hoffmann, N., Vilsbøll, T., Chenchar, A., Jensen, M., Grevengoed, T. J., et al. (2018) · Molecular Metabolism

Fibroblast Growth Factor ResearchAlcohol Consumption and Health Effects

Cited by 94

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD

Seghieri, M., Christensen, A. S., Andersen, A., Solini, A., Knop, F. K., & Vilsbøll, T. (2018) · Frontiers in Endocrinology

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 92

Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes

Højberg, P. V., Zander, M., Vilsbøll, T., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetologia

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 89

Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series

Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., Fink-Jensen, A., et al. (2023) · Therapeutic Advances in Psychopharmacology

Pharmacology and Obesity TreatmentSchizophrenia research and treatment

Cited by 88

Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents

Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 85

LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

Hagemann, C. A., Jensen, M. S., Holm, S., Gasbjerg, L. S., Byberg, S., Skov-Jeppesen, K., Hartmann, B., Holst, J. J., Dela, F., Vilsbøll, T., et al. (2022) · Cell Reports Medicine

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 81

The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review

Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 80

Mechanism of Metabolic Advantages After Bariatric Surgery

Knop, F. K., & Taylor, R. (2013) · Diabetes Care

Bariatric Surgery and OutcomesDiabetes Treatment and Management

Cited by 77

Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects

Knop, F. K., Konings, E., Timmers, S., Schrauwen, P., Holst, J. J., & Blaak, E. E. (2013) · Diabetic Medicine

Sirtuins and Resveratrol in MedicineNatural Antidiabetic Agents Studies

Cited by 72

How glucagon-like peptide 1 receptor agonists work

Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 71

Hemodynamic Effects of Glucagon: A Literature Review

Petersen, K. M., Bøgevig, S., Holst, J. J., Knop, F. K., & Christensen, M. B. (2018) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 68

GIP and GLP-1 receptor antagonism during a meal in healthy individuals

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 68

Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease

Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides

Adipokines, Inflammation, and Metabolic DiseasesDiabetes Treatment and Management

Cited by 67

Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide

Faurschou, A., Knop, F. K., Thyssen, J. P., Zachariae, C., Skov, L., & Vilsbøll, T. (2014) · Acta Diabetologica

Psoriasis: Treatment and PathogenesisSkin Diseases and Diabetes

Cited by 65

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes

Bergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 62

Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs

Rehfeld, J. F., Knop, F. K., Asmar, A., Madsbad, S., Holst, J. J., & Asmar, M. (2018) · Scandinavian Journal of Gastroenterology

Diabetes Treatment and ManagementGallbladder and Bile Duct Disorders

Cited by 62